Country | Type | Number | Dated | Case |
Japan | Published Application | 2023-527768 | 06/30/2023 | 2020-120 |
China | Published Application | CN116157536A | 05/23/2023 | 2020-120 |
European Patent Office | Published Application | 4153772 | 03/29/2023 | 2020-120 |
Additional Patent Pending
Cas13 or Cas12 enzymes can be programmed with a guide RNA that recognizes a desired target sequence, activating a non-specific RNase or DNase activity. This can be used to release a detectable label. On its own, this approach is inherently limited in sensitivity and current methods require an amplification of genetic material before CRISPR-base detection.
Current methods of programming Cas13 or Cas12 enzymes to release a detectable label require an amplification of genetic material before CRISPR-base detection and are inherently limited in sensitivity. In these existing scenarios, a guide RNA recognizes a desired target sequence, activating a non-specific RNase or DNase activity.
In contrast, this invention includes an all-in-one detection modality with an internal Nuclease Chain Reaction (NCR) and an amplifying, feed-forward loop. The technology generates an exponential signal upon detection of a target nucleic acid.
nucleic acid, nuclease chain reaction, NCR, Cas13, Cas12